PT Saptausaha Gemilangindah Tbk (SAGE)
Jul 31, 2025 - SAGE was delisted (reason: acquired by SUPN)
8.68
-0.02 (-0.23%)
Inactive · Last trade price on Jul 30, 2025

Sage Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
9726---
Upgrade
Market Cap Growth
28.19%-73.19%----
Upgrade
Enterprise Value
11827---
Upgrade
Last Close Price
0.000.000.00---
Upgrade
PE Ratio
-1455.3784.18---
Upgrade
PS Ratio
16.046.6618.29---
Upgrade
PB Ratio
0.530.391.40---
Upgrade
P/TBV Ratio
0.530.391.40---
Upgrade
EV/Sales Ratio
18.607.8218.93---
Upgrade
EV/EBITDA Ratio
-124.8071.77---
Upgrade
EV/EBIT Ratio
-168.4172.97---
Upgrade
Debt / Equity Ratio
0.080.080.050.070.090.07
Upgrade
Debt / EBITDA Ratio
-21.262.420.691.71-
Upgrade
Asset Turnover
0.030.050.080.130.100.02
Upgrade
Inventory Turnover
0.070.120.210.390.300.06
Upgrade
Quick Ratio
0.190.460.950.040.040.02
Upgrade
Current Ratio
4.825.154.720.330.360.32
Upgrade
Return on Equity (ROE)
-1.09%0.03%2.30%9.62%4.33%-5.67%
Upgrade
Return on Assets (ROA)
-0.49%0.15%1.21%3.02%1.42%-1.02%
Upgrade
Return on Capital (ROIC)
-0.51%0.16%1.62%6.30%3.15%-1.67%
Upgrade
Return on Capital Employed (ROCE)
-0.30%1.90%9.60%4.80%-
Upgrade
Earnings Yield
-2.07%0.07%1.19%---
Upgrade
Buyback Yield / Dilution
9.37%0.00%-25.06%--180.45%-281.98%
Upgrade
Updated Apr 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q